SG11201808990QA - Compositions for topical application of compounds - Google Patents

Compositions for topical application of compounds

Info

Publication number
SG11201808990QA
SG11201808990QA SG11201808990QA SG11201808990QA SG11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA SG 11201808990Q A SG11201808990Q A SG 11201808990QA
Authority
SG
Singapore
Prior art keywords
international
compositions
pct
california
april
Prior art date
Application number
SG11201808990QA
Other languages
English (en)
Inventor
Jacob Waugh
Original Assignee
Illustris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Illustris Pharmaceuticals Inc filed Critical Illustris Pharmaceuticals Inc
Publication of SG11201808990QA publication Critical patent/SG11201808990QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/62—Coated
    • A61K2800/624—Coated by macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201808990QA 2016-04-12 2017-04-12 Compositions for topical application of compounds SG11201808990QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321626P 2016-04-12 2016-04-12
PCT/US2017/027275 WO2017180788A1 (en) 2016-04-12 2017-04-12 Compositions for topical application of compounds

Publications (1)

Publication Number Publication Date
SG11201808990QA true SG11201808990QA (en) 2018-11-29

Family

ID=59999163

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808990QA SG11201808990QA (en) 2016-04-12 2017-04-12 Compositions for topical application of compounds

Country Status (11)

Country Link
US (2) US20170290778A1 (https=)
EP (1) EP3442488A4 (https=)
JP (1) JP2019513799A (https=)
KR (1) KR20190022476A (https=)
CN (1) CN109152702A (https=)
AU (1) AU2017250267A1 (https=)
CA (1) CA3020400A1 (https=)
IL (1) IL262180B2 (https=)
MX (1) MX2018012486A (https=)
SG (1) SG11201808990QA (https=)
WO (1) WO2017180788A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
SG160357A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
US11040090B2 (en) * 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
MY210233A (en) * 2017-10-11 2025-09-04 Illustris Pharmaceuticals Inc Methods and compositions for topical delivery
WO2019118928A1 (en) 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
KR102189632B1 (ko) * 2018-03-09 2020-12-11 전남대학교산학협력단 신규 균주 페니실리움 애시둠 및 이의 용도
KR101899413B1 (ko) * 2018-05-03 2018-09-18 주식회사 케어사이드 피부 감염의 예방 또는 치료용 조성물
JP7430140B2 (ja) 2018-06-26 2024-02-09 久光製薬株式会社 マイクロニードルデバイス及びそれを製造する方法
KR102088104B1 (ko) * 2018-06-29 2020-03-11 호서대학교 산학협력단 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CN111825775B (zh) * 2019-04-18 2021-11-02 复旦大学 密枝圆柏多糖及其制备方法和在制备抗肿瘤药物中的用途
CN110090193B (zh) * 2019-05-14 2022-04-12 东方爱堡(北京)母婴健康科技有限公司 一种具有减脂功效的祛痘保湿精华液及其制备方法
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
CN115279788A (zh) * 2019-12-24 2022-11-01 黛芙生物科学公司 用于治疗银屑病和其他疾病的外用环孢霉素
CN111281980B (zh) * 2020-02-05 2025-01-24 芽米科技(广州)有限公司 一种水溶性γ-聚谷氨酸-替米考星复合物及其制备方法
CN111110831B (zh) * 2020-02-20 2023-08-08 柳州市工人医院 一种溃疡糊剂及其制备方法
CN111297884B (zh) * 2020-04-02 2021-03-30 中国农业科学院蜜蜂研究所 腺苷在蜜蜂病毒感染防治中的应用
CN111329846A (zh) * 2020-04-24 2020-06-26 云南伦扬科技有限公司 一种阴道杀菌贴膜及其制备方法
CN111587861A (zh) * 2020-05-21 2020-08-28 广州市穗升有害生物防治中心 引诱箱
WO2023048748A1 (en) * 2020-08-10 2023-03-30 Ziropa, Inc. Compositions and methods for topical delivery
WO2023080886A1 (en) * 2020-09-29 2023-05-11 Ziropa, Inc. Compositions and methods for pain relief and numbing
JP2024519426A (ja) * 2020-09-29 2024-05-14 ジロパ・インコーポレイテッド 疼痛の緩和及び麻痺のための組成物及び方法
MX2023004648A (es) * 2020-10-22 2023-05-18 Pfizer Suspensiones acuosas sin peg para administracion parenteral.
CN114617974B (zh) * 2020-12-10 2023-10-03 中国科学院苏州纳米技术与纳米仿生研究所 一种多肽白蛋白纳米粒及其制备方法和应用
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
AU2022210856A1 (en) 2021-01-22 2023-08-17 Egis Gyógyszergyár Zrt. Topical formulation containing modified phospholipid compounds
CA3172145A1 (en) * 2021-02-05 2022-08-11 Yelena Zolotarsky Recombinant collagen skincare compositions and methods of use thereof
WO2022232161A1 (en) * 2021-04-26 2022-11-03 Sypherion, Llc Inhibitors of nsp1 for treatment of sars-cov-2
CN113332238A (zh) * 2021-06-09 2021-09-03 四川恒通动保生物科技有限公司 一种加米霉素的复合溶液剂的制备方法
JP7141025B1 (ja) * 2021-11-11 2022-09-22 エルデシエロ プライベート リミテッド 化合物、組成物、方法、及び製造方法
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
CN117186177B (zh) * 2022-05-31 2024-08-23 中国农业大学 一种具有降尿酸活性的鸭血球蛋白肽及其制备方法
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
WO2024007014A2 (en) * 2022-06-30 2024-01-04 Board Of Trustees Of The University Of Arkansas Process for treating livestock exposed to toxic forage using melatonin compositions
CN117582442A (zh) * 2022-08-18 2024-02-23 智泽童康(广州)生物科技有限公司 双嘧达莫在制备防治蚊虫叮咬的产品中的应用
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
CN116098882A (zh) * 2023-04-06 2023-05-12 山东诚创蓝海医药科技有限公司 一种含利多卡因丙胺卡因的组合物及其制备方法
CN116791274B (zh) * 2023-06-16 2026-03-27 福建恒安集团有限公司 一种超柔软爽滑纯棉无纺布的制备方法及其应用
CN116870001B (zh) * 2023-08-11 2024-08-27 云南中医药大学 吲哚-3-甲酸衍生物与氟康唑联合在制备抗耐药白念珠菌药物中的应用
CN117427027B (zh) * 2023-12-21 2024-04-23 舒芙雅生物科技有限公司 一种祛痘组合物及其制备方法
US12357725B1 (en) 2024-05-30 2025-07-15 King Saud University Clinical dressing loaded with coffee extract
CN120284984B (zh) * 2025-04-25 2025-10-17 首都医科大学附属北京胸科医院 一种抗结核分枝杆菌感染的化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
IT1260148B (it) * 1992-04-17 1996-03-28 Fidia Spa Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
US8728510B1 (en) * 2002-03-15 2014-05-20 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing a bioadhesive material
US7956180B2 (en) * 2004-05-27 2011-06-07 Novozymes A/S Dried and agglomerated hyaluronic acid product
WO2006063021A2 (en) * 2004-12-07 2006-06-15 Surmodics, Inc. Coatngs with crystallized active agents (s)
US7727537B2 (en) * 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
CA2876767C (en) * 2005-10-03 2018-07-10 Mark A. Pinsky Liposomes comprising hyaluronic acid and their use in improved skin care
JP5481197B2 (ja) * 2006-12-26 2014-04-23 ボミ・パテル・フラムローゼ 高色素沈着した皮膚のための皮膚美白組成物
WO2008124169A2 (en) * 2007-04-10 2008-10-16 The Trustees Of The University Of Pennsylvania Islet cells composition and methods
US20100008878A1 (en) * 2007-08-09 2010-01-14 Foodchemifa Co., Ltd Propylene glycol hyaluronate, and skincare preparation for external use comprising same
DE102008034265A1 (de) * 2008-07-22 2010-01-28 Beiersdorf Ag Wirkstoffkombination aus Anisfruchtextrakt und Hyaluronsäure
KR101610985B1 (ko) * 2008-11-14 2016-04-08 히스토젠, 인코포레이티드 암 치료를 위한 세포외 기질 조성물
US8679470B2 (en) * 2008-11-28 2014-03-25 Luromed Llc Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications
WO2010135449A1 (en) * 2009-05-19 2010-11-25 Plurogen Therapeutics, Inc. Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing
US20110020271A1 (en) * 2009-05-20 2011-01-27 Humacyte, Inc. Elastin for soft tissue augmentation
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
US20110305737A1 (en) * 2010-06-09 2011-12-15 NY Derm LLC Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology
FR2971711B1 (fr) * 2011-02-18 2014-06-13 Isp Investments Inc Composition cosmetique comprenant un extrait de petit epeautre en tant qu'agent activateur de la synthese des proteines de la matrice extracellulaire
WO2014134532A1 (en) * 2013-02-28 2014-09-04 Ventrix, Inc. Methods and compositions for tissue therapy and analysis
US10337406B2 (en) * 2013-02-28 2019-07-02 United Technologies Corporation Method and apparatus for handling pre-diffuser flow for cooling high pressure turbine components
WO2014138235A1 (en) * 2013-03-05 2014-09-12 Liberatoscioli Dante Apparatus for relieving back pain

Also Published As

Publication number Publication date
AU2017250267A1 (en) 2018-11-08
US20190008795A1 (en) 2019-01-10
IL262180A (en) 2018-11-29
IL262180B1 (en) 2025-08-01
EP3442488A1 (en) 2019-02-20
IL262180B2 (en) 2025-12-01
CN109152702A (zh) 2019-01-04
KR20190022476A (ko) 2019-03-06
US20170290778A1 (en) 2017-10-12
MX2018012486A (es) 2019-06-06
JP2019513799A (ja) 2019-05-30
WO2017180788A1 (en) 2017-10-19
CA3020400A1 (en) 2017-10-19
EP3442488A4 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201909949XA (en) Targeted immunotolerance
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201908391XA (en) Methods for modulating an immune response
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201907023UA (en) Method of reducing neutropenia
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof